(Q33963503)

30 July 2017

title

Strategies for pharmacologic treatment of high functioning autism and Asperger syndrome (English)

1 reference

30 July 2017

0 references

0 references

high-functioning autism

1 reference

Kenneth E Towbin

1

1 reference

30 July 2017

publication date

1 January 2003

1 reference

Child and Adolescent Psychiatric Clinics of North America

30 July 2017

published in

1 reference

30 July 2017

volume

12

1 reference

30 July 2017

issue

1

1 reference

30 July 2017

page(s)

23-45

1 reference

The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Prevalence of autism in a United States population: the Brick Township, New Jersey, investigation

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Pervasive Developmental Disorders in Preschool Children

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

The epidemiology of autism: a review.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Validity and neuropsychological characterization of Asperger syndrome: convergence with nonverbal learning disabilities syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Two-year outcome of preschool children with autism or Asperger's syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Non-significance of early speech delay in children with autism and normal intelligence and implications for DSM-IV Asperger's disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Does DSM-IV Asperger's disorder exist?

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

The classification of autism, Asperger's syndrome, and pervasive developmental disorder

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Speech and prosody characteristics of adolescents and adults with high-functioning autism and Asperger syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Delayed language onset as a predictor of clinical symptoms in pervasive developmental disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Abnormal ventral temporal cortical activity during face discrimination among individuals with autism and Asperger syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Abnormal processing of social information from faces in autism.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

The functional neuroanatomy of social behaviour: changes in cerebral blood flow when people with autistic disorder process facial expressions.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Social intelligence in the normal and autistic brain: an fMRI study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

The external validity of Asperger disorder: lack of evidence from the domain of neuropsychology

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Brain anatomy and sensorimotor gating in Asperger's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Pharmacological interventions in autism: theoretical and practical issues

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Pharmacological treatment of mood disturbances, aggression, and self-injury in persons with pervasive developmental disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

An analysis of maladaptive behaviors in persons with autism, PDD-NOS, and mental retardation.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Commentary: considerations on the characterization and treatment of self-injurious behavior.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Reward signaling by dopamine neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Behavioral treatment of self-injury, 1964 to 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Differential response of operant self-injury to pharmacologic versus behavioral treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Paroxetine treatment of aggression and self-injury in persons with mental retardation

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Fluoxetine Treatment of Children and Adults with Autistic Disorder and Mental Retardation

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Clomipramine in adults with pervasive developmental disorders: a prospective open-label investigation.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Clonidine treatment of hyperactive and impulsive children with autistic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Open trial effects of beta-blockers on speech and social behaviors in 8 autistic adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

A pilot study of nadolol for overt aggression in developmentally delayed individuals.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

An open trial of divalproex sodium in autism spectrum disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

A systematic review of the use of atypical antipsychotics in autism

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Risperidone in children with autism and serious behavioral problems

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Case series: use of ziprasidone for maladaptive symptoms in youths with autism

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Anxiety in high-functioning children with autism

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Comorbid anxiety symptoms in children with pervasive developmental disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Role of the serotonin transporter gene in the behavioral expression of autism

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

The amygdala and related structures in the pathophysiology of autism

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an open-label study.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Amotivational syndrome associated with selective serotonin reuptake inhibitors in children and adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Life events and depression in children with pervasive developmental disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Psychopharmacology of 5-HT(1A) receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Brain Serotonin1A Receptor Binding Measured by Positron Emission Tomography With [11C]WAY-100635

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Brain serotonin2 receptors in major depression: a positron emission tomography study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

State and trait abnormalities in serotonin function in major depression

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

The serotonin system in autism

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Attention function and dysfunction in autism

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Use of methylphenidate in the treatment of children with autistic disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Anxiolytics, adrenergic agents, and naltrexone

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Anatomic and behavioral aspects of frontal-subcortical circuits

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Locus coeruleus and regulation of behavioral flexibility and attention.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

1 reference

7 January 2021

Assessment in multisite randomized clinical trials of patients with autistic disorder: the Autism RUPP Network. Research Units on Pediatric Psychopharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Multisite, double-blind, placebo-controlled trial of porcine secretin in autism

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Effects of intravenous secretin on language and behavior of children with autism and gastrointestinal symptoms: a single-blinded, open-label pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Genetics of austim: complex aetiology for a heterogeneous disorder

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

A genomewide screen for autism susceptibility loci

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Pharmacogenetics and the serotonin system: initial studies and future directions.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Antipsychotic-related QTc prolongation, torsade de pointes and sudden death

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

Tolerability profile of atypical antipsychotics in children and adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS1056-4993%2802%2900049-4

7 January 2021

10.1016/S1056-4993(02)00049-4

Identifiers

DOI

1 reference

30 July 2017

1 reference